- About this Journal ·
- Abstracting and Indexing ·
- Advance Access ·
- Aims and Scope ·
- Article Processing Charges ·
- Articles in Press ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Case Reports in Pediatrics
Volume 2014 (2014), Article ID 185923, 4 pages
Two Cases of Progressive Familial Intrahepatic Cholestasis Type 2 Presenting with Severe Coagulopathy without Jaundice
1Division of Pediatric Gastroenterology, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Baltimore, MD 21287, USA
2Division of Pediatric Gastroenterology, Texas Children’s Hospital, 6621 Fannin Street, Houston, TX 77030, USA
Received 24 February 2014; Revised 8 May 2014; Accepted 20 May 2014; Published 2 June 2014
Academic Editor: Junji Takaya
Copyright © 2014 Eric Tibesar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Progressive familial intrahepatic cholestasis (PFIC) type 2 results from a mutation in the bile salt exporter pump, impeding bile acid transport. Patients usually present with jaundice, pruritus, growth failure, and fat soluble vitamin deficiencies. We present two patients diagnosed with PFIC type 2 due to severe coagulopathy and bleeding without jaundice.
Case A is a healthy 5-month-old female who presented to a local hospital with scratching to the point of bleeding and ecchymoses on her abdomen, back, and legs. She had no history of jaundice since birth and jaundice was not noted at several doctors’ visits prior to this presentation. Physical examination showed neither icterus nor hepatosplenomegaly. Initial labs demonstrated AST 223 U/L, ALT 334 U/L, total bilirubin 3.4 mg/dL, direct bilirubin 2.8 mg/dL, GGT 33 U/L, partial thromboplastin time (PTT) 90.8 seconds, prothrombin time (PT) > 120.0 seconds, and INR > 13.7. She received a one-time intravenous vitamin K with repeat INR of 1.0 and then was admitted for further evaluation. Of note, she was treated with IV cefotaxime at the outside hospital due to a positive urine culture for Escherichia coli, and this was continued for a full seven-day course.
Cholestasis persisted with a peak direct bilirubin of 7.5 mg/dL. An abdominal ultrasound showed normal hepatic echotexture and biliary system without focal lesions. Infectious work-up included negative serologies for CMV, EBV, HIV, HSV, HCV, and HBV. As vitamin K deficiency was thought to be from cholestasis related malabsorption, fat soluble vitamin studies were performed and revealed a vitamin D (25-OH) level of <5 ng/mL, normal vitamin A, and an alpha-tocopherol level of 0.8 mg/L. Total serum bile acids were elevated at 205.3 umol/L (normal; 4.5–19.2 umol/L). Percutaneous liver biopsy revealed mild chronic portal inflammation, periportal fibrosis, ballooning hepatocytes, significant cholestasis, and early bile duct loss with ductular proliferation (see Figures 1 and 2). No bile salt exporter pump (BSEP) staining was performed. Serum sent for genetic evaluation revealed heterozygous mutations in the ABCB11 gene (c.908(+1)G>A/c.3692 G>A (R1231Q)), confirming the diagnosis of progressive familial intrahepatic cholestasis (PFIC) type 2.
Following discharge, she suffered from intractable pruritus despite the use of ursodiol, rifampin, cholestyramine, and hydroxyzine. She underwent an internal ileal diversion at 12 months with no relief of significant pruritus and continued presence of high total bile acid level of 147.4 umol/L and subsequently an internal biliary diversion at 15 months, again without relief of pruritus and presence of even higher total bile acid level of 239.2 umol/L. Growth had been normal, but the patient had low vitamin E and D levels, despite large dose supplementation. She was listed for living related donor liver transplant at this point.
Case B is a 14-year-old male, clinically diagnosed with Alagille syndrome as an infant due to cholestasis without evidence of jaundice and a liver biopsy that showed paucity of intrahepatic bile ducts. Past medical history is significant for intracerebral hemorrhage during infancy, presumably due to vitamin K deficiency, leading to life-long seizure disorder and residual left-sided hemiparesis. He was treated with phenytoin for seizure control and followed up closely by the pediatric liver service due to concerns about fat soluble vitamin deficiencies, cholestasis, and poor growth.
At the age of 14, he presented to an outside emergency room with leg pain and increased bruising. Jaundice was not noted. Labs showed PT of 40 seconds and PTT of 120 seconds. He received a one-time intramuscular dose of 30 mg vitamin K, and repeat labs showed PT of 16.7 seconds and PTT of 35.0 seconds. Total bilirubin was 0.6 mg/dL and GGT was normal (see Table 1 for comparison to Case A). No antibiotics were given and he was discharged home the next day, with close follow-up arranged in the pediatric GI clinic.
Over the following 15–18 months, he developed jaundice with worsening cholestasis and increased pruritus. At the age of 16, due to increased jaundice, he underwent endoscopic retrograde cholangiopancreatography (ERCP) and percutaneous liver biopsy. The ERCP was normal. Liver biopsy showed marked canalicular and hepatocellular cholestasis, with mild to moderate portal and lobular fibrosis including BSEP staining (see Figures 3 and 4). There was no paucity of intrahepatic bile ducts, with findings inconsistent with Alagille syndrome. Because of continued jaundice and cholestasis, genetic testing was done, showing mutations in the ABCB11 gene (c.890A>G; p.Q297G/c.2343+1 G>T), confirming the diagnosis of PFIC type 2 . Case B reached adult age without transplantation.
Discussion. These two cases demonstrate an unusual presentation of PFIC type 2 in that both had severe coagulopathy without the presence or the history of jaundice in their clinical manifestations. Although both patients eventually developed a more obvious feature of jaundice, their initial presentations of cholestasis and coagulopathy in the absence of jaundice were concerning enough to warrant further investigations in order to provide proper management. In a recent analysis of presenting signs and symptoms of patients with BSEP mutations, the most common finding was jaundice (73% of patients), with 9% of patients presenting with manifestations of vitamin deficiency . Of those 9% of patients, 58% presented without clinical signs of jaundice, although the exact vitamin deficiency and presence of clinical bleeding were not mentioned . There was no mention of any patient specifically presenting with coagulopathy or clinical bleeding, corrected with vitamin K, in the absence of jaundice.
Patients with PFIC type 2 can be diagnosed based on mutations in the ABCB11 gene, which encodes the BSEP protein. To date, there are more than 100 mutations that have been discovered in the ABCB11 gene, leading to a 70% reduction or complete absence of bile salts removed from the liver . Two of the more common mutations that have been found include the missense mutations E297G and D482G, found in up to 30% of European patients with PFIC type 2 . A retrospective analysis of 84 patients with ABCB11 gene mutations found that 61% of them had one or two alleles with these more common missense mutations . Ten were noted to have coagulopathy from vitamin deficiency upon presentation, with three being noted to have the D482G mutation . Both patients in this report had genetic analysis, without evidence of either of the two more common mutations.
In Case A the first mutation is c.3692 G>A in exon 27 . The predicted protein effect is R1231Q, which does not lead to an abnormal splice site but causes a missense mutation. This results in an immature protein or delayed maturation of BSEP, presumably lowering its function . This mutation was also reported in 2 patients who had homozygous and compound heterozygous mutations [5, 7]. The patient with homozygous mutations developed severe fibrosis and underwent liver transplantation at the age of 2.9 years. The other mutation at the splice site, c.908+1G>A in intron 9 of ABCB11, has also been reported by Strautnieks et al. . In that study, this mutation was found in a compound heterozygote for c.908+1G>A with another common missense mutation c.1445A>G. The c.1445A>G is predicted to cause p.Asp482Gly; however, its true effect is aberrant splicing which leads to translation of a truncated protein . The progression of liver disease in this patient was actually slow.
In Case B, his first mutation is 890 A>G in exon 9 . The predicted protein effect is E297G or p.Glu297Gly. The other mutation is c.2343+1 G>T which is a mutation at splice site, 5′ intron 19, a novel splice site change. This compound heterozygous mutation was reported in Case B’s sister who developed persistent cholestasis and bridging fibrosis at the age of 2 years, biliary cirrhosis at the age of 3 years, and cholangiocarcinoma and died at the age of 4 .
There are technical challenges to the exploration of the mRNA consequences of the splice site mutations by sequencing the corresponding cDNA. Since expression of BSEP protein in extrahepatic tissues is low, the only way to get sufficient mRNA is sampling the explanted liver and conserving the RNAse inhibitors immediately at the time of surgery, which was not feasible in both cases. We can assume that Case B must have similar mutations as his sister whose mRNA sequencing was performed and published by Scheimann et al. . On the other hand, from a clinical perspective, one would assume that homozygotes of c.3692 G>A would manifest a more severe presentation compared to a compound heterozygote of c.908(+1)G>A/c.3692 G>A, similar to Case A. In theory, the expected result of c.908+1G>A could be exon 9 skipping with deletion, frameshift mutation resulting in a premature stop codon and protein truncation. However, less likely events include skipping of more than one exon or cryptic splice site activation. More importantly, the absence of the wild type transcript, which originates from the allele carrying the splice site mutation, is rather complicated in a compound heterozygote, especially with a normally transcribed allele carrying a 2.3 kb downstream missense mutation. In one report, biallelic BSEP mutations were described in PFIC type 2 children with a tendency to have lower bile acid concentration and lower age at liver transplantation than those with one truncating and one missense mutation; an expected correlation with a severe mutation with vitamin malabsorption and deficiencies was not reported . Perhaps there is yet more to learn about genotype and phenotype association to understand the molecular function of the BSEP protein.
In this report we conclude that patients who present with cholestasis and significant coagulopathy that respond to vitamin K should have congenital liver diseases such as PFIC included in their differential diagnosis though cholestasis may not be pronounced as a common clue in the diagnosis. Genetic analysis for mutations in the ABCB11 gene can aid in diagnosis after ruling out common causes of cholestasis. Further study in larger cohorts of PFIC type 2 populations may reveal more specific genotype-phenotype correlations.
|PTT:||Partial thromboplastin time|
|BSEP:||Bile salt exporter pump|
|PFIC:||Progressive familial intrahepatic cholestasis.|
Conflict of Interests
The authors declare that there is no potential conflict of interests to disclose.
The authors would like to acknowledge the help of Dr. Milton Finegold and Dr. Robert Anders with assistance in interpretation of the pathology slides and Dr. Milan Jirsa for interpretation of PFIC2 mutations in Case A in preparing this paper.
- A. O. Scheimann, S. S. Strautnieks, A. S. Knisely, J. A. Byrne, R. J. Thompson, and M. J. Finegold, “Mutations in bile salt export pump (ABCB11) in two children with progressive familial intrahepatic cholestasis and cholangiocarcinoma,” The Journal of Pediatrics, vol. 150, no. 5, pp. 556–559, 2007.
- L. Pawlikowska, S. Strautnieks, I. Jankowska et al., “Differences in presentation and progression between severe FIC1 and BSEP deficiencies,” Journal of Hepatology, vol. 53, no. 1, pp. 170–178, 2010.
- Genetics Home Reference, ABCB11 gene, 2013, http://ghr.nlm.nih.gov/gene/ABCB11.
- H. Hayashi, T. Takada, H. Suzuki, H. Akita, and Y. Sugiyama, “Two common PFIC2 mutations are associated with the impaired membrane trafficking of BSEP/ABCB11,” Hepatology, vol. 41, no. 4, pp. 916–924, 2005.
- S. S. Strautnieks, J. A. Byrne, L. Pawlikowska et al., “Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families,” Gastroenterology, vol. 134, no. 4, pp. 1203–1214, 2008.
- J. A. Byrne, S. S. Strautnieks, G. Ihrke et al., “Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre-messenger RNA splicing,” Hepatology, vol. 49, no. 2, pp. 553–567, 2009.
- L. Alvarez, P. Jara, E. Sánchez-Sabaté et al., “Reduced hepatic expression of farnesoid X receptor in hereditary cholestasis associated to mutation in ATP8B1,” Human Molecular Genetics, vol. 13, no. 20, pp. 2451–2460, 2004.
- A. Davit-Spraul, M. Fabre, S. Branchereau et al., “ATP8B1 and ABCB11 Analysis in 62 children with normal gamma-glutamyl transferase Progressive Familial Intrahepatic Cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history,” Hepatology, vol. 51, no. 5, pp. 1645–1655, 2010.